These results led to the development of L9LS, a long–half-life human IgG1 monoclonal antibody that targets another highly conserved junctional PfCSP epitope. It was produced by expression in a ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer’s disease.

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

Created by Biolojic Design, AU-007 is the first human IgG1 monoclonal antibody designed by leveraging artificial intelligence to enter a human clinical trial. The antibody’s novel mechanism of ...

Originally developed for multiple myeloma, felzartamab is a fully human IgG1 monoclonal CD38 antibody that depletes target cells through antibody-dependent cellular cytotoxicity and phagocytosis.

a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill ...

The Food and Drug Administration (FDA) has granted Fast Track designation to CSX-1004, a human IgG1 monoclonal antibody under investigation as a potential therapy to prevent fentanyl-related overdose.

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the ...

The new company, called Timberlyne Therapeutics, will be centered around the IgG1 monoclonal antibody CM313, for which Keymed has sold the ex-China rights for an undisclosed upfront payment ...